Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × sargramostim × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Lung Neoplasms 3 Wilms Tumor 2 Mesothelioma 2 Kidney Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Unspecified Childhood Solid Tumor, Protocol Specific 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdoid Tumor 1 Retinoblastoma 1 Pancreatic Neoplasms 1 Optic Nerve Glioma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Myelodysplastic Syndromes 1 Medulloblastoma 1 Liver Neoplasms 1 Leukemia 1 Hepatoblastoma 1 Familial ependymoma 1 Congenital Abnormalities 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

pembrolizumab 12 Injections 12 Paclitaxel 10 Docetaxel 9 Cisplatin 8 Capecitabine 8 senaparib 7 Nivolumab 7 Fluorodeoxyglucose F18 7 Bevacizumab 7 toripalimab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Cyclophosphamide 6 tislelizumab 5 fludarabine 4 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡